Condition
Proteus Syndrome
Total Trials
5
Recruiting
2
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Recruiting2
Completed2
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT04316546Phase 2RecruitingPrimary
MK-7075 (Miransertib) in Proteus Syndrome
NCT00001403RecruitingPrimary
Study of Proteus Syndrome and Related Congenital Disorders
NCT02594215Phase 1CompletedPrimary
Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome
NCT03317366UnknownPrimary
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies
NCT01369953Completed
Informed Consent for Whole Genome Sequencing: Ideals and Norms Referenced by Early Participants
Showing all 5 trials